About CAGE Bio

Nitin has been actively engaged in pharmaceutical product development in 

the industry since Feb 1998, when (at Elan Pharmaceuticals), he first started studying interactions between powders and polymer surfaces to improve the efficiencies of pulmonary dry powder inhalation products for asthma and COPD. He moved into formulation and process development thereafter and became fully entrenched in pharmaceutical dosage form development. He has actively contributed to various drug delivery products from new chemical entities to drug delivery applications for known molecules. In 2006, he started working on a transdermal product for post- operative pain at ALZA Corporation. He led the development of the next-generation version of IONSYS, a drug-device combination transdermal product. He believed in the technology and the value of the product, so when the company terminated the program, he joined with outside investors and co-created Incline Therapeutics to get this product approved and to the market.

Jeff is a veteran of the pharmaceutical industry with 40 years of

leadership experience in developing and commercializing new

medical therapies. He has invented products leading to

significant improvements in patient care and has numerous

patents issued by the USPTO in healthcare. He has a track

record of success in developing new companies from start-up,

through IPO and M&A exits. He was the co-founder and COO at

ZS Pharma, acquired by Astra Zeneca in 2015 for $2.7 billion.

He is the inventor of the Mucinex product line for Adams

Respiratory Therapeutics. He developed and executed the R&D

and Regulatory strategy as VP of Development and Regulatory

Affairs, which subsequently was acquired by Reckitt Benckiser

for $2.3 billion in 2007. Jeff held senior positions at Encysive

Pharmaceuticals, Medeva Americas, Marion Merrell Dow and

Abbott Laboratories.  Jeff is currently serving as the President 

and CEO of Renibus Therapeutics which he co-founded.